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ABSTRACT 
Objectives: Oxidative stress is involved in cystic fibrosis (CF), but no 
guidelines for its assessment or its treatment exist. Our aim was to evaluate a 
test that measures the whole antioxidant capability in CF children. 
Methods: The whole blood antioxidant capability was assessed by the KRL 
test in 44 CF children (24 boys). We recorded several data on the same day: 
anthropometric measures, pulmonary function, CF severity scores, and plasma 
nutritional and inflammatory parameters (proteins, vitamins, erythrocyte fatty 
acids, micronutrients). We performed univariate and multivariate analyses with 
linear regression models. 
Results: The mean age at the first KRL assessment was 12.2 ± 3.8 years. The 
factors correlated to a diminution of the antioxidant capacity were mostly 
related to the severity of pulmonary disease (FEV1, acute exacerbation, and 
congestion). In multivariate analysis, the correlation between Brasfield score 
and erythrocyte antioxidant potential remained significant (β=-0.611, p<0.001). 
Among nutritional factors, 6/3 ratio was significantly correlated to 
erythrocyte antioxidant potential (β=-1.213, p=0.01).  
Conclusion: The whole antioxidant capability, measured by the KRL test, 
should be a useful biomarker to assess oxidative stress in CF patients. This 
study suggests that 6/3 ratio should be relevant nutritional end-point in the 





It was already demonstrated that oxidative stress was involved in the 
pathophysiology of cystic fibrosis (CF), while recurrent pulmonary infections, 
chronic pulmonary inflammation and abnormal lung epithelium homeostasis 
increase the release of oxidative molecules, and antioxidants like 
micronutrients and fat-soluble vitamins are decreased [1-4]. However, no 
guidelines are established for the follow-up of oxidative stress or antioxidant 
potential in clinical practice in CF.  
Oxidative stress is defined as an abnormal oxidant/antioxidant balance, 
secondary to either an increase of oxidants or a decrease of antioxidants [1]. In 
CF, large amounts of reactive oxygen species (ROS) are released by 
neutrophils that are present in bronchial lumen [1]. Other sources of ROS come 
from bronchial cilated and alveolar type II epithelial cells, and Pseudomonas 
aeruginosa [1]. These ROS alter bacteria phagocytosis. ROS are second 
messengers that can activate, through NF-B pathway, the transcription of 
inflammatory cytokines, mainly IL-6 and IL-8 [1]. Oxidants can also increase 
lipid peroxidation, producing several pro-inflammatory lipid mediators. 
Oxysterols, which are produced by oxidation of cholesterol, are increased in 
CF [7]. The oxidation of arachidonic acid (AA) produces acid 8-isoprostane 
prostaglandin F2[8]. Plasma level of this eicosanoid is increased after 
pulmonary exacerbations [8]. The imbalance is also due to a decreased level of 
glutathione (GSH), an impaired NO metabolism, and an abnormal intracellular 
H2O2 production [1]. Antioxidants present at respiratory surface are ascorbate, 
urate, -tocopherol, GSH, and mucins [6]. GSH is the only antioxidant present 
in larger amount in epithelial lining fluid than in plasma; however GSH levels 
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are decreased to 5-10% in epithelial lining fluid and to 50% in plasma of CF 
patients [6].   
Nutritional status is important in CF management. It is associated with 
both pulmonary status and survival [9]. In the setting of oxidative stress, 
protein malnutrition contributes to decreased albumin level and secondarily to 
low GSH levels [6]. Albumin can not provide all cysteine required for GSH 
production [6]. Pancreatic insufficiency causes malabsorption of fat-soluble 
antioxidants such as carotenoids, vitamin E, and coenzyme Q-10 [1, 6]. There 
is also an abnormal fatty acid pattern in CF that is characterized by a decrease 
in the plasma levels of linoleic acid and docosahexaenoic acid (DHA) and an 
increase in the levels of AA and eicosapentaenoic acid [10, 11]. These 
abnormalities are present even in well-nourished children, suggesting an 
involvement of the protein CFTR in fatty acid metabolism rather than fat 
malabsorption [11]. AA promotes the production of inflammatory mediators 
while 3 polyunsaturated fatty acids (PUFA), DHA and eicosapentaenoic acid 
(EPA), are involved in the resolution of inflammation [1, 12]. Around 90% of 
CF patients require pancreatic enzyme replacement therapy (PERT) and fat-
soluble vitamin supplementation. However, the amount of antioxidant vitamin 
supplementation could be different to obtain normal plasma vitamin levels or 
to correct oxidant/antioxidant balance [5, 6]. For example, CF Foundation 
recommends 40-400 IU/d of vitamin E to normalize plasma levels [13]. To 
reach an antioxidant effect, 1600 IU/d of vitamin E were required in 
hypercholesterolemic subjects [1]. However, some studies reported that high-
dosage vitamin E supplementation increased risk of heart failure, coagulopathy, 
and death [6, 14]. Carotenoid supplementation had also positive results on 
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oxidative stress in CF trials. Vitamin E and carotenoid induced a decrease of 
markers of lipid peroxidation, like 8-isoprostane prostaglandin F2 and 
malondialdehyde respectively [6]. However, the clinical relevance of these 
improvements is unknown. Of note, large cancer prevention trials that used -
tocopherol and -carotene (ATBC trial) or -carotene and retinyl palmitate 
(CARET trial) lead to an excess lung cancer incidence and an excess mortality 
in the active vitamin treatment arm [15]. The cardiovascular mortality was also 
increased. Finally, micronutrient deficiencies, mainly selenium and zinc, which 
are frequent in CF, can alter the function of enzymatic antioxidants [1, 6]. Zinc 
is a cofactor of superoxide dismutase and selenium is en essential component 
of GSH peroxidase and thioredoxin reductases [6]. 
Oxidative stress can be assessed by several biomarkers [1, 5, 6]. The 
aim of this study was to use a test that measured the whole antioxidant 
capability in CF children, using a rapid and standardized test (KRL test). We 
also looked for a correlation with appropriate clinical, biochemical, and 
radiological parameters.    
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2. Subjects and methods 
2.1. Subjects 
Between 09/11/2006 and 09/03/2008, oxidative stress was measured on 
blood samples in our pediatric CF unit. We retrospectively analysed blood 
samples of 44 CF children collected during this period. Children were assessed 
once (n=19), twice (n=22) or three times (n=3), resulting in a total of 72 
samples. During this out-clinic visit, anthropometric parameters (weight, height, 
body mass index (BMI) z-score, height to weight (H/W) ratio) and respiratory 
status (congestion, exacerbation, forced expiratory volume in 1 second (FEV1) 
(%) and maximum midexpiratory flow (MMEF) [16]) were noted in a 
computerized database. Their treatments, like fat-soluble vitamins, PERT, 
selenium supplementation, and ursodeoxycholic acid, were registered. A single 
physician (FB) also retrospectively evaluated CF severity scores (Shwachman 
and Brasfield scores). Shwachman score is composed of 4 items (general 
activity, physical examination, nutrition status, and radiological findings). The 
note of each item is 5, 10, 15, 20, or 25, ranging from severe to excellent. Thus, 
Shwachman score can be excellent (86-100), good (71-85), average (56-70), 
poor (41-55), or severe (≤40). Brasfield radiological score describes several 
items (air trapping, linear markings, nodular cystic lesions, large lesions, and 
general severity. This score varies from 0 to 25 (normal to severe). 
We recorded the anthropometric parameters and FEV1 values obtained 
6 months before to look for patient evolution prior to oxidative stress analysis. 
We calculated the evolution of BMI z-score and FEV1 during this period, 
respectively (z-BMI – z-BMIM-6)/ z-BMIM-6 and (FEV1 – FEV1 M-6)/ FEV1 M-6, 
respectively defined as BMIev and FEV1ev. 
 8 
2.2. Biological parameters  
A blood sample was usually drawn for biological analyses. For this 
study, we collected the values of liver function tests (aspartate amino-
transferase (AST), alanine amino-transferase (ALT), gamma-glutamyl 
transpeptidase (GGT)), blood cell count, creatinin level, nutritional and 
inflammatory proteins (prealbumin, albumin, retinol binding protein, 
ceruloplasmin, transferin, orosomucoid, and C reactive protein), micronutrients 
(zinc, cupper, and selenium), fat-soluble vitamins (retinol, and -tocopherol), 
and lipids levels (total cholesterol, triglycerides, and erythrocyte fatty acids).  
Erythrocyte fatty acid composition was determined by capillary gas 
chromatography. Red blood cells were separated from plasma by centrifugation 
at 1730 g for 10 minutes at 4 ◦C and washed three times with an equal volume 
of cold physiological (9 g/L NaCl) solution. Lipid extraction was performed 
with a 3-mL chloroform/methanol mixture (V/V). Phospholipids were isolated 
by thin layer chromatography on silica gel 60 plates (E Merck, Darmsmat, 
Germany) using petrol ether/diethylether/acetic acid (80 V/20 V/1 V) as the 
mobile phase. Fatty acid methyl esters were generated by transmethylation of 
the phospholipid fraction in 5% acetyl chloride/95% methanol and separated by 
gas chromatography. The fatty acid analysis was carried out with a Dani GC 
1000 gas chromatograph equipped with a CP-Wax 58 capillary column, 50 m 
in length, 0.25 mm external diameter, 0.2 µm thickness of the stationary phase 
(Varian Inc., Les Ulis, France), with helium 1 mL/min as carrier gas and a 
programmed temperature (60 to 230°C). Programmed temperature vaporization 
injector and flame ionization detector were used. 1-2 dinonadecanoylsn 
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glycerol-3 phosphatidyl choline (Interchim, Montluc¸on, France) was used as 
internal standard. 
2.3. Oxidative stress measurement 
KRL test (“SPIRAL” laboratories, Couternon, France) is currently used 
to test the capability of erythrocytes to resist a standardized production of free 
radicals (http://www.nutriteck.com/sunyatakrl.html). The extracellular and 
intracellular antioxidant defenses contribute to maintain red blood cell 
membrane integrity and function until cell lysis. Blood samples were taken into 
evacuated tubes containing EDTA and kept at 4°C. Total blood or red blood 
cells separated from plasmas by centrifugation at 1730 g for 10 min at 4°C 
were diluted to 1/50 in isotonic saline solution and submitted to organic free 
radicals produced at 37°C under air atmosphere from the thermal 
decomposition of a 27 mmol/L solution of 2,2´-azobis (2-amidinopropane) 
dihydrochloride during 3 hours. Cell lysis was recorded using a 96-well 
microplate reader by measuring the optical density decay at 620 nm. Half-lysis 
time (T1/2 in min), the time at which 50% of cells have been lysed, is 
determined by calculating the time corresponding to OD1/2 according to the 
curve equation OD=f(time) and the highest value of the curve (Vmax). Results 
are expressed as mean of T1/2 of erythrocytes (T1/2 erythro) and T1/2 of 
whole blood cells (T1/2 whole blood).  
2.4. Data analysis 
Numerical data were expressed as mean  SD (minimum-maximum). A 
descriptive analysis of the main patient’s clinical and biological characteristics 
(displayed in Table 1) was performed using a principal component analysis 
with varimax rotation.  Univariate analysis was performed with non-parametric 
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tests, Mann-Whitney test and Spearman correlation test. Then factors 
independently associated with T1/2 erythro/T1/2 whole blood were identified 
using stepwise multiple linear regression models (entry threshold: F test p-
value <0.1). All these analyses were performed on 44 cases, i.e. one per 
patient. When more than one analysis was performed for one patient, we chose 
the first measure. Then, a second multivariate analysis was performed on all 
available measures using linear models fitted with the Generalized Estimating 
Equation method. We therefore analysed 72 cases, accounting for the non-
independence of measures among patients who had more than one oxidative 
stress evaluation. We used the SPSS 17.0 software (SPSS Inc., Chicago, IL, 
USA). All tests were two-sided and considered statistically significant at 
p<0.05. 
3. Results 
3.1. Description of the population 
In this study, 44 children (24 boys and 20 girls) were included. The 
mean age at the first KRL assessment was 12.2  3.8 (5.9-19.1). Clinical 
characteristics of these children were reported on Table 1. Among these 
children, 5 (11.4%) had a z-BMI lower than -2; the H/W ratio was lower than 
85% in 7 children (15.9%), between 85-90% in 3 children (7%). None of these 
malnourished children was on enteral feeding at that time. Ninety-one percent 
of these patients were pancreatic insufficient. They were supplemented with 
vitamin A (43%), vitamin E (91%) and selenium (64%) according to their 
respective blood values. Forty-three percent of patients were on 
ursodeoxycholic acid treatment.          
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Their respiratory status was correct. The mean value of FEV1 was 94% 
(Table 1). Only 2 patients had a FEV1 ≤ 50 %. Congestion and exacerbation 
were reported respectively in 57% and 14% of the visits. Pseudomonas 
aeruginosa was found in 16% of the cultures performed in all of the visits. 
Only 2 patients did not have an antibiotic prophylaxis. At the time of 
evaluation, 15 patients (34%), i.e 25 visits (35%), were treated with 
itraconazole. In 38% of the visits, Brasfield score was ≥ 10. Finally, in 86% of 
the visits, the patients had a good or excellent score of Shwachman (≥ 70); 
none of them had a severe score. 
The C reactive protein was available in 42 patients. Results were < 3 
mg/L, between 3-10 mg/L, and > 10 mg/L, respectively in 69%, 21%, and 10% 
of the patients. Other biochemical results were reported in Table 2. 
3.2. Oxidative status 
 The mean of T1/2 whole blood (n=72) was 90.3  11.4 min (68.5-
121.7) (normal range: 85.15-102.60). The mean of T1/2 erythro (n=60) was 
72.0  14.8 min (24.9-125.0) (normal range: 65.35-81.78). As expected, the 
correlation between T1/2 whole blood and T1/2 erythro was statistically 
significant (=0.525, p=0.001). 
3.3. Principal component analysis 
The plane identified by the first two factorial axes, was found to explain 
38% of the total inertia in the data (Figure 1). The variables that are close to 
one of the axes are correlated together. For example, the first factorial axis 
(factor 1) was mainly positively correlated to FEV1 and retinol/RBP, and 
mainly negatively correlated to orosomucoid, ceruloplasmin, triglycerides, and 
Brasfield score. The second factorial axis (factor 2) was mainly positively 
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correlated to retinol, pre-albumin, and RBP. Inversely, the principal component 
analysis should suggest that age and GGT were not correlated to the other 
variables.  
3.4. Univariate analysis (Table 3) 
There is an association between sex and antioxidant potential. T1/2 
whole blood and T1/2 erythro were significantly shorter in females than males, 
92.2 ± 12.4 vs. 88.4 ± 10.2 min (p=0.011), and 75.0 ± 11.5 vs. 68.9 ± 17.2 min 
(p=0.052) respectively. There was no correlation of T1/2 whole blood or T1/2 
erythro with age, and anthropometric parameters. We did not find any 
difference between CF patients who were treated or not with antioxidants 
(vitamin A, vitamin E, ursodeoxycholic acid (UDCA), or selenium). The 
amount of PERT was negatively correlated to T1/2 erythro (ρ=-0.36, p=0.039). 
As it could be expected, the levels of selenium in the serum were positively 
correlated to T1/2 erythro (ρ=0.35, p=0.047) and T1/2 whole blood (ρ=0.44, 
p=0.004). Concerning PUFA of membrane phospholipids of erythrocytes, the 
6/3 ratio was negatively correlated to T1/2 erythro (ρ=-0.37, p=0.030). 
However, there was no correlation with levels of PUFA (DHA, EPA, and AA), 
retinol, and -tocopherol. 
Pulmonary functional tests revealed that only FEV1 was positively 
correlated to T1/2 erythro (ρ=0.39, p=0.018). Concerning the pulmonary 
infectious diseases of these patients, Pseudomonas aeruginosa colonisation was 
not correlated to antioxidant potential. However, patients that were on 
itraconazole treatment had lower antioxidant potential than patients that were 
not, statistically significant for T1/2 erythro, 65.7 ± 12.6 min vs. 75.8 ± 14.9 
min (p=0.025). To note, these patients were not treated with itraconazole for 
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acute broncho-pulmonory aspergillosis but for chronic colonisation. A shorter 
time of T1/2 erythro was found for acute exacerbation and congestion, 73.3 ± 
15.7 min vs. 65.2 ± 5.3 min (p=0.022) and 76.1 ± 18.6 min vs. 68.7 ± 10.1 min 
(p=0.009). Finally, Brasfield score was negatively correlated to T1/2 eryhtro 
(ρ=-0.48, p=0.03) and T1/2 whole blood (ρ=-0.32, p=0.036). 
We expected a negative correlation of antioxidant potential with 
inflammatory proteins. If there was a trend with C-reactive protein (CRP) and 
T1/2 erythro (p=0.063), we found a negative correlation of inflammatory 
proteins with T1/2 erythro: orosomucoid (ρ=-0.62, p<0.001) and ceruloplasmin 
(ρ=-0.57, p<0.001). The number of blood leucocytes was negatively associated 
with T1/2 whole blood (ρ=-0.36, p=0.018) and T1/2 erythro (ρ=-0.39, p=0.025). 
  3.5. Multivariate analysis 
For T1/2 erythro, 3 parameters were independently associated: 
Brasfield score, 6/3 ratio, and levels of selenium in the serum. However, 
this latter parameter could be excluded when we analysed all the results of 
KRL test performed for the same patient. Finally, Brasfield score and 6/3 
ratio remained independently negatively correlated to T1/2 erythro, β=-0.611 
(p<0.001) and β=-1.213 (p=0.013) respectively. 
For T1/2 whole blood, 2 parameters were independently associated: sex 
and MMEF. After accounting for all the available measures, only the sex 
remained significantly correlated to T1/2 whole blood (p=0.015).   
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4. Discussion: 
 The KRL test represents the capability of a person to react to an 
oxidative stress. In our study, T1/2 erythro was significantly associated with a 
decrease of plasma level of selenium. The decrease of this antioxidant could 
alter the selenium-dependant GSH peroxidase, as it was reported [1]. T1/2 
erythro was also associated with pulmonary congestion and exacerbation, i.e. 
may be with an increase of ROS in the lungs. To our knowledge, the 
correlation of oxidative stress and Brasfield score was not previously described. 
In our study, this score was the only respiratory parameter that remained 
statistically significant in multivariate analysis. More than air trapping, this 
association could be due to bronchiectasis. In the literature, oxidative stress 
was present during acute respiratory exacerbations and it improved after 
treatment of exacerbation [18]. The oxidation of proteins that were present in 
bronchoalveolar lavage fluids was negatively correlated to FEV1 values [19]. 
However, oxidative stress remains present in stable CF patients and it could 
also contribute to chronic pulmonary inflammation [5]. Similarly, a recent 
study assessed plasma and cellular oxidative stress biomarkers in stable adults 
with bronchiectasis (36 CF, and 54 without CF), and in 50 healthy controls 
[20]. Oxidative stress biomarkers were increased in patients with 
bronchiectasis compared with controls, without difference between CF and not 
CF patients.  
 The relation of good nutritional status and pulmonary function is well 
established [21]. We did not find any association between antioxidant 
capability, assessed by the KRL test, and anthropometric parameters. However, 
the fact that the amount of PERT was associated in univariate analysis with 
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T1/2 erythro should suggest that pancreatic insufficiency by itself rather than 
clinical nutritional status is involved in oxidative stress in CF. Lezo et al. 
recently reported that CF patients with pancreatic insufficiency had higher 
levels of lipid peroxidation biomarkers than patients with pancreatic 
sufficiency [5]. We did not find any significant differences between oxidative 
stress and fat-soluble vitamins. The antioxidant capabilities of patients that 
were not treated with antioxidant vitamins were similar to those of 
supplemented patients. Abnormalities of fatty acids that occurs in CF seems to 
be of importance [7, 10]. In multivariate analysis, we found a significant 
negative correlation of 6/3 ratio and T1/2 erythro. The increase of 6/3 
ratio is associated with a decrease of antioxidant potential of CF patients, with 
synthesis of pro-inflammatory lipid mediators and reduction of resolvins, 
involved in the resolution of inflammation [12]. A limitation of our study is 
that we did not test these lipid mediators, but they were not routinely available. 
In further studies, we should assess plasma levels of protaglandins (PGE2), 
leucotriens (LTB4), and eicosanoids (5-HETE) that are the products of the 
oxidation of AA by cyclooxygenase and 5-lipoxygenase. They could be of 
better interest than AA, EPA, and DHA levels that were not associated with 
oxidative stress in our study. However, ratio of 6/3 or AA/DHA could be of 
greater importance than the quantity of fatty acids [7, 10]. 
In order to effectively manage oxidative stress in CF, we could 
hypothesize that: (i) plasma antioxidant normal values are too low in the setting 
of CF; (ii) antioxidant levels within the airway are more important than the 
plasma levels; (iii) trials are needed to determine appropriate antioxidant 
regimen [5, 6]. New formulations of fat-soluble vitamins and antioxidants have 
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been tested since few years [22, 23]. The formulation increased plasma levels 
of -carotene, -tocopherol and CoQ-10. Improvement of their antioxidant 
score was correlated to a decreased airway inflammation assessed by levels of 
IL-8 and total neutrophils in sputum. This score combined the values of these 
levels of several antioxidants pre and post-treatment. However, this score was 
complex and only determined in 10 patients. Moreover, pre and post-levels of 
IL-8 and especially total neutrophils only decreased in few patients [22]. The 
formulation is now commercialised as AquADEKs®, a formulation containing 
several fat-soluble vitamins, water-soluble vitamins, micronutrients, and 
antioxidants. An open-label non-randomised study enrolled 14 CF patients [23]. 
The authors only found an improvement of plasma levels of some antioxidants 
(-carotene, CoQ-10, and -tocopherol). No correlation was found with urine 
8-isoprostane levels. In recent reviews, details on antioxidant trials in CF were 
summarized [1, 6]. Our data suggest that the KRL test is an interesting tool to 
assess antioxidant potential in CF. Moreover, its correlation with pulmonary 
status could dispense of the measure of BAL oxidative biomarkers that are 
more invasive. This test could allow to follow the antioxidant potential of CF 
children and to monitor the effectiveness of antioxidant intervention.   
In conclusion, the present study demonstrated that the whole 
antioxidant capability, measured by the KRL test, should be a useful biomarker 
to assess oxidative stress in CF patients. It was associated with pulmonary 
status. The better respiratory parameter correlated to antioxidant potential was 
Brasfield score. The efficiency of the KRL test was greater in erythrocytes than 
in whole blood cells. This study should suggest that 6/3 ratio could be more 
relevant than fat-soluble antioxidant vitamin levels to assess oxidative stress in 
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CF. Finally, an interventional trial is required to evaluate the usefulness of this 
test to detect post-treatment improvements.    
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Figure 1. Principal Component Analysis, plane of the first two components 
(Factor 1 and Factor 2). To note, this two factorial axes explained 38% of the 




AA: arachidonic acid, ALT: alanine amino-transferase, AST: aspartate amino-
transferase, DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, 
erythrZn:  erythrocyte Zinc, FEV1: forced expiratory volume in 1 second, 
GGT: gamma-glutamyl transpeptidase, HW: height to weight ratio, TG: 
triglycerides, TotalSe: whole blood Selenium, w6w3: 6/3 ratio, zBMI: z-




 Table 1: Clinical characteristics of CF children 
 
 
N mean SD Min Max 
Age (year) 44 12.2 3.8 5.9 19.1 
z-BMI 44 -0.5 1.2 -3.8 2.7 
H/W ratio 44 96 11 68 122 
FEV1 (%) 44 94 22 33 142 
Brasfield score 44 7.5 3.3 1 14 
Shwachman score 44 82 9 60 100 
PERT  
(U lipase/kg/d) 
40 4501 1478 2455 8471 
Sputum positive negative 
Staphylococcus aureus 54 18 
Pseudomonas aeruginosa 13 59 
























 4 other mutation other mutation 
 
 
FEV1: forced expiratory volume in 1 second, H/W ratio: height to weight ratio, 
PERT: pancreatic enzyme replacement therapy, z-BMI: z-score of body mass 
index. 
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Table 2: Biochemical characteristics of CF children 
 
 N mean SD Min Max 
AST (ULN) 40 0.7 0.2 0.3 1.6 
ALT (ULN) 40 0.6 0.4 0.2 2.0 
GGT (ULN) 40 0.5 0.3 0.2 2.0 
Albumin (g/L) 42 39.4 4.1 31.0 49.9 
Pre-albumin (g/L) 42 0.20 0.05 0.11 0.31 
Orosomucoid (g/L) 42 0.92 0.37 0.40 2.50 
Ceruloplasmin (g/L) 42 0.39 0.15 0.20 0.90 
Transferrin (g/L) 42 2.9 0.4 2.1 3.9 
Retinol binding protein (g/L) 42 0.033 0.010 0.013 0.062 
Whole blood selenium 
(µmol/L) 
38 
0.97 0.20 0.63 1.45 
Serum selenium (µmol/L) 41 0.86 0.19 0.53 1.39 
Serum zinc (µmol/L) 42 12.9 2.0 8.5 17.0 
Erythrocyte zinc (µmol/L) 42 165 31 95 220 
Retinol (mg/L) 42 0.38 0.12 0.15 0.68 
Retinol/RBP 42 0.85 0.08 0.67 1.06 
-tocopherol (mg/L) 42 8.5 2.2 4.8 13.6 
Total cholesterol (mmol/L) 41 3.14 0.64 1.70 4.90 
Triglycerides (mmol/L) 41 0.83 0.37 0.38 1.90 
EPA (mg/L) 42 10.5 4.2 3.5 22.8 
DHA (mg/L) 42 67.2 18.4 33.8 115.6 
AA (mg/L) 42 257.9 28.9 199.0 328.0 
6/3 42 4.7 1.1 2.8 8.6 
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AA: arachidonic acid, ALT: alanine amino-transferase, AST: aspartate amino-
transferase, DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, GGT: 
gamma-glutamyl transpeptidase, ULN: upper limit of normal. 
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Table 3: Univariate analysis of continuous variables (Spearman 
correlation test) 
 T1/2 whole blood T1/2 erythro 
  p  p 
Anthropometric parameters 
Age -0.067 0.665 -0.206 0.229 
Weight 0.012 0.940 -0.096 0.579 
Height -0.040 0.797 -0.112 0.517 
H/W 0.193 0.209 0.107 0.533 
Pulmonary functional tests and severity scores  
FEV1 0.122 0.428 0.392 0.018 
MMEF 0.279 0.066 0.329 0.050 
Brasfield score -0.317 0.036 -0.475 0.003 
Shwachman score 0.168 0.276 0.321 0.056 
Treatment     
UDCA (mg/kg/d) 0.134 0.387 0.234 0.169 
PERT (U lipase/kg/d) -0.125 0.443 -0.361 0.039 
Biological parameters     
Leucocytes -0.363 0.018 -0.385 0.025 
Serum Se 0.435 0.004 0.349 0.047 
Total Se 0.278 0.091 0.058 0.759 
Serum Cu -0.153 0.340 -0.354 0.043 
Retinol 0.050 0.752 0.241 0.170 
-tocopherol 0.116 0.465 -0.041 0.819 
Orosomucoid -0.236 0.132 -0.617 <0.001 
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Ceruloplasmin -0.232 0.140 -0.568 <0.001 
DHA 0.200 0.203 0.232 0.187 
EPA 0.188 0.233 0.280 0.108 
AA -0.126 0.428 -0.130 0.465 
6/3 -0.266 0.088 -0.372 0.030 
 
AA: arachidonic acid, Cu: cupper, DHA: docosahexaenoic acid, EPA: 
eicosapentaenoic acid, FEV1: forced expiratory volume in 1 second, H/W: 
height to weight ratio, MMEF: maximum midexpiratory flow, PERT: 
pancreatic enzyme replacement therapy, Se: selenium, T1/2 erythro : half-lysis 
time of erythrocytes, T1/2 whole blood : half-lysis time of whole blood cells, 
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